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granules containing perforin. Products treated with LLME dem-
onstrated a median depletion of 94.9% CD56 cells, 75.8 %
CD8 cells, but only 37.2% CD4 cells. Patients initially re-
ceived 10e4 (haploidentical (HAPLO)), 10e5 (HLA identical un-
related (URD)), or 10e6 (HLA identical sibling (SIB)) CD3
cells/kg in cohorts of 3, and were eligible for additional infusions at
a one log higher dose after 28 days if there was no evidence of
GVHD or the CD4 count was less than the target of 100 cells/ml.
The initial dose was escalated by one log in subsequent cohorts if
no complications were observed in the previous cohort. Nine
patients received grafts from SIBs (4 at 10e6, 5 at 10e7), six from
URDs (3 at10e5, 3 at 10e6), and three from HAPLOs (3 at 10e4).
All patients had pre-DLI CD4 counts of 5.0 cells/ml, and re-
ceived 1 to 3 infusions post PCT. Since ATG was used during
PCT cytoablation, the ﬁrst DLI infusions were administered after
ATG levels were2 mcg/ml. After DLI #1, 6/8 evaluable matched
SIB recipients and 2/6 evaluable URD recipients demonstrated
early recovery of donor derived CD4 cells prior to day 35 s/p
DLI, with a median CD4 count of 139 cells/ul (range 57–471).
Ten of these achieved a CD4 count above 100 after 1–3 total
infusions. In contrast, none of the haploidentical recipients (receiv-
ing the smallest doses) had an increase in CD4 counts. Five
patients developed GVHD (Grade I–II (n 4), Grade III (n  1
following 410e7 LLME DLI). In recovering patients, spectra-
type analysis of CD4 cells comparing DLI before LLME treat-
ment with lymphocytes recovered from the patients post DLI
demonstrated that 94% of the resolvable Vb families were equally
complex. Perforin positive cells, as well as adenovirus (n 2), EBV
(n  1) and CMV (n  2) speciﬁc lymphocytes, also recovered
post-PCT in these patients. These preliminary results suggest that
LLME treated DLI can accelerate CD4 reconstitution without
causing severe GVHD.
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REGULATORY T CELL (Treg) RECONSTITUTION FOLLOWING T CELL
DEPLETED ALLOGENEIC STEM CELL TRANSPLANTATION—KINETICS
OF RECOVERY AND RELATIONSHIP WITH GVHD
Rezvani1, K., Mielke1, S., Ahmadzadeh1, M., Savani1, B., Kilical1, Y.,
Hensel1, N., Kurlande1, R., Barrett1, A.J. National Institutes of Health,
Bethesda, MD.
Regulatory T cells (Treg) that speciﬁcally express the Foxp3
transcriptional repressor are instrumental in the maintenance of
tolerance. They may suppress GVHD and regulate lymphocyte
recovery after SCT. Animal transplantation models show that
Tregs suppress GVHD. However, current data in humans on the
impact of Tregs on GVHD following SCT is conﬂicting, possibly
due to differences in surface phenotyping techniques used to char-
acterize these cells. To characterize Treg recovery and the rela-
tionship with acute GVHD we studied CD4 CD25 Foxp3 T
cells reconstitution in the ﬁrst 120 days following a T-depleted
allogeneic SCT in 17 patients with leukemia. We used surface
phenotyping for CD4 and CD25, intracellular staining for Foxp3
protein, Foxp3 gene expression and functional assays to deﬁne
Treg cells. We found a strong correlation between Foxp3 gene
expression and Foxp3 CD4 T cell number by intracellular
staining. There was a direct correlation between Foxp3 gene ex-
pression and CD4 CD25 T cell numbers in healthy donors.
Interestingly, this strict correlation was lost in patients with leu-
kemia post-SCT due to a disparity between CD4 CD25 and
CD4 Foxp3 T cell numbers in some patients, most likely
related to expansion of the CD4 CD25 Foxp3 effector T cell
population. Although, the proportion of CD4 T cells that are
CD25 reached normal as early as 30 days post-SCT (median 5.0,
range 2.0–8.9), absolute circulating Treg numbers were low in the
ﬁrst 30–45 days post-SCT reaching near-normal levels by day 120,
indicating that Tregs generally recover at a similar rate to CD4
CD25 T cells. However higher day 30 Foxp3 gene expression
inversely correlated with the development of grade II–IV acute
GVHD (P  .02) suggesting that suppressor activity rather than
Treg numbers may be more relevant to GVHD suppression. Chi-
merism analysis was performed on sorted CD4 CD25 and
CD4 CD25 T cell fractions from leukapheresis samples col-
lected 120 days post transplant on 7 patients. In most patients, the
expanded Treg population was enriched in cells of donor origin.
Our results suggest that early Treg reconstitution may affect the
development of GVHD. These results suggest that Treg function
(as measured by Foxp3 gene expression) is important in controlling
alloreactions post-transplant. Our data support the use of ex vivo
expanded activated Tregs given in the ﬁrst 30 days post SCT to
prevent acute GVHD.
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GANCICLOVIR SUPPRESSES HUMAN T LYMPHOCYTE PROLIFERATION
IN VITRO
Battiwalla, M.1, Wu, Y.1, Radovic, M.3, Nakamura, R.2,
Bajwa, R.P.S.1, Elefante, A.1, Segal, B.1, Almyroudis, N.1,
McCarthy, P.L.1 1. Roswell Park Cancer Institute, Buffalo, NY; 2. City
of Hope, Duarte, CA; 3. State University of New York, Buffalo, NY.
Clinically signiﬁcant cytomegalovirus (CMV) infection in allo-
geneic blood or marrow transplant recipients has dramatically
declined in recent years by prophylactic or preemptive therapy
with ganciclovir (GCV). However, patients at risk for CMV reac-
tivation (seropositive donor and/or recipient) consistently have
worse outcomes than patients who are not at risk for CMV reac-
tivation. We have previously shown that even in the absence of
overt CMV disease, persisting post-transplant antigenemia pre-
dicts for increased late relapse and treatment failure (Nakamura et
al BBMT 2004). In other words, frequent CMV reactivation serves
as a surrogate for impaired post-transplant immune reconstitution.
To explain the observed association between CMV reactivation
and relapse, we also raised the possibility that several weeks of
GCV therapy could exert a deleterious effect on a fragile immune
system. We present in vitro data that GCV inhibits normal human
T-lymphocytes and identify the mechanism of immunosuppres-
sion. Human PBMCs were extracted from normal volunteers and
subjected to mitogenic (PHA) or antigen-speciﬁc (CMV-antigen)
stimulation in the absence or presence of varying concentrations of
GCV. Thereapeutic concentrations of GCV greatly reduced both
PHA-induced as well as antigen-speciﬁc T cell proliferation in
vitro compared to foscarnet. The uptake of 3[H]-thymidine by
PBMCs after 5 days incubation in RPMI-10% AB serum was
reduced by 35% at peak therapeutic concentrations (10 mcg/ml) of
GCV as opposed to 73% by Tacrolimus (10ng/ml). GCV did not
induce apoptosis of the Raji (B cell, Burkitt’s leukemia) cell line nor
did it induce apoptosis of normal peripheral blood lymphocytes in
the presence or absence of stimulation. Flow cytometry-based
BrdU incorporation assays show that GCV exerts a time-depen-
dent impairment of DNA synthesis in lymphocytes. Collectively,
these results show that GCV is a potent suppressor of T-lympho-
cyte proliferation in vitro at therapeutic concentrations and the
likely mechanism of action is inhibition of DNA synthesis. GCV
therapy in BMT patients probably increases the level and/or du-
ration of overall T cell immunosuppression and may account for
the differences in clinical outcome.
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INSULIN-LIKE GROWTH FACTOR I IS A POSITIVE REGULATOR OF
THYMIC FUNCTION
Chu, Y.-W.1, Schmitz, S.1, Choudhury, B.1, Gress, R.1 Experimental
Transplantation and Immunology Branch, National Cancer Institute,
Bethesda, MD.
Neuroendocrine growth factors have been implicated to play a
role in regulating thymic function and serve as potential agents to
accelerate thymic T cell production following hematopoietic stem
cell transplantation (HSCT). We present evidence supporting in-
sulin-like growth factor I (IGF-1) as a thymic regulator. Contin-
uous 2-week infusions of IGF-1 (100 ug/day) into young adult
mice resulted in signiﬁcant increases in muliple thymocyte sub-
populations, including early CD4-CD8- subpopulations and ear-
liest thymocyte precursors (ETP). BrdU incorporation with con-
tinuous oral administration was also increased in these populations,
suggesting a stimulatory effect of IGF-1 on thymocyte prolifera-
tion and developmental kinetics. Expansion of peripheral naive T
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cell populations without changes in cell division (as measured by
Ki67 expression) and recent thymic emigrants (as measured by T
cell receptor excision circles TREC) were observed with 4-week
courses of IGF-1 treatment. Signiﬁcantly, these changes were not
observed in similarly treated thymectomized mice, indicating that
effects of IGF-1 on peripheral T cell populations resulted primar-
ily from enhanced thymic output. IGF-1 administration also af-
fected thymic epithelial cell (TEC) turnover as measured by BrdU
incorporation, with observable shifts in TEC subpopulations in the
thymic cortex and medulla as enumerated by ﬂow cytometry.
Immunohistoﬂuorescence of extracellular matrix (ECM) in IGF-1
treated young, aged, and RAG KO mice were signiﬁcant for
changes in laminin distribution. Finally, mice lacking IGF-1 re-
ceptor (IGF-1R) signaling on T cells were generated through T
cell speciﬁc cre-mediated deletion of the IGF-1R high-afﬁnity
binding site (LCK-cre/loxIGF1R). Compared to wild-type litter-
mates, LCK-cre-loxIGF1R mice exhibited a decrease in the num-
ber of CD4 CD8 thymocytes, thymic TREC, splenic naive T
cell populations, and splenic TREC. These results demonstrate: (1)
IGF-1 enhances the recruitment of thymocyte precursors, expands
thymocyte subpopulations, and increases thymic output; (2) IGF-1
affects TEC turnover and ECM distribution, suggesting a mech-
anism by which IGF-1 inﬂuences thymocyte development; and (3)
IGF-1R signaling is required for the maintenance of normal thy-
mocyte and peripheral T cell populations. Together, the results
support the concept of the use of neuroendocrine growth factors
such as IGF-1 in preserving and/or enhancing recovery of thymic
function following HSCT.
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ANTI-MINOR HISTOCOMPATIBILITY ANTIGEN SPECIFIC CD8 MEMORY
CELLS RESPOND DIFFERENTLY TO ANTIGEN AND ANTIGEN-INDEPEN-
DENT ACTIVATION IN THE SPLEEN AND MARROW COMPARTMENTS
FOLLOWING HCT
Shatry, A.1, Levy, R.B.1 University of Miami Miller School of Medicine,
Miami, FL.
We are interested in studying how CD8 memory cells respond in
recipients following progenitor cell transplants. Antigen-speciﬁc
CD8 TM against the immunodominant H60 antigen in B6 mice
contribute to resistance against MHC-matched BALB.B marrow.
To examine CD8 TM responses to this antigen, B6 mice were
sensitized 2 with BALB.B antigen (B6BALB.B) and 1, 5, and 22
days later, H60-speciﬁc CD8 TM in the spleen and marrow were
analyzed for degranulation as assessed by CD107a expression. One
day following antigen administration, degranulation by CD8 TM
was equivalent (90%) in host spleen and marrow. Five days later,
degranulation of splenic H60 CD8 TM (60%) was 3 higher
(22%) versus cells in the marrow compartment. These levels de-
creased to 25% and 12%, respectively, in the spleen and marrow 3
weeks post antigen boost. These results indicated that CD8 TM
effector-like activity is induced asymmetrically in the 2 compart-
ments and this activity may be differentially regulated in these
locations. We then compared MiHA-speciﬁc CD8 TM in the
marrow and spleen after antigen-independent (lymphopenia) acti-
vation. Highly enriched (	95% pure) CFSE labeled or unlabeled
donor splenic CD8 T cells from B6BALB.B mice were adoptively
co-transplanted with syngeneic marrow to ablatively conditioned
(9.0 Gy) syngeneic hosts. Three days post-transfer, donor CD8
TM in recipient marrow and spleen were analyzed for CFSE
dilution and degranulation including H60 CD8 TM cells. Donor
H60 CD8 TM in the marrow underwent multiple cycles of
division in contrast to the spleen, indicating that the marrow
compartment provided superior support for this initial homeostatic
proliferation. Interestingly, 92% of donor H60 CD8 TM in
recipient spleens expressed CD 107a compared to 42% in the
marrow compartment. In total, these ﬁndings indicate that whereas
the marrow supported greater homeostatic proliferation of donor
CD8 TM versus the spleen, the latter compartment was the pre-
ferred site for effector-like activity induced by lymphopenic con-
ditions. These ﬁndings underscore the importance of hematopoi-
etic compartments in shaping the diversity and differentiation of
allospeciﬁc CD8 TM responses in the transplant setting.
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IMMUNE MONITORING WITH iTAGTM MHC TETRAMERS FOR PREDIC-
TION OF RECURRENT OR PERSISTENT CYTOMEGALOVIRUS (CMV) IN-
FECTION IN ALLOGENEIC STEM CELL TRANSPLANT (SCT) RECIPIENTS:
A PROSPECTIVE MULTICENTER CLINICAL TRIAL
Boeckh, M.1, Nakamura, R.2, Cornelissen, J.J.3, Zaia, J.A.2, Forman,
S.J.2, Gaal, K.2, Brooimans, R.A.3, Gratama, J.W.3, Gasior, G.H.4,
Sullivan, L.A.4, Boyce, C.S.4, Southwick, P.C.4 1. Fred Hutchinson
Cancer Research Center, Seattle, WA; 2. City of Hope National Medical
Center, Duarte, CA; 3. Erasmus Medical Center, Rotterdam, Nether-
lands; 4. Beckman Coulter, San Diego, CA.
Background: CMV infection is an important cause of morbidity
and mortality in SCT recipients despite the introduction of routine
post-transplant virologic monitoring and the use of potent antiviral
agents. This prospective multicenter study evaluated the use of
tetramers in monitoring CMV-speciﬁc T cell recovery following
allogeneic SCT to predict patients at risk for CMV-related com-
plications. Methods: Patients were tested every 2 weeks and mon-
itored for up to 1 year post-transplant. iTAg™ MHC Tetramers
(Beckman Coulter, San Diego) were used to enumerate CMV-
speciﬁc CD8 T cells by ﬂow cytometry using a single-platform
absolute counting method. The following tetramers were included:
pp50: A0101 VTEHDTLLY; pp65: A0201 NLVPMVATV,
B0702 TPRVTGGGAM, B3501 IPSINVHHY; IE-1: B0801
ELRRKMMYM. All patients underwent weekly surveillance by
pp65 antigenemia or DNAemia with preemptive antiviral therapy.
Results: Data were analyzed for 83 CMV-seropositive recipients
with 3 or more tetramer values. Median follow-up was 9 months
(range 2–12). Delayed recovery of CMV-speciﬁc CD8 T cells
(7 cells/mL in all blood samples during the ﬁrst 65 days post-
transplant) predisposes patients to CMV-related complications
(Table 1). These patients are 2.6 times more likely to develop
recurrent or persistent CMV infection, 4.8 times more likely to
develop CMV disease, 2.4 times more likely to develop fatal com-
plications, and 2.2 times more likely to develop one of more of
these outcomes than patients showing rapid recovery. Rapid re-
covery (7 cells/mL in any blood sample during the ﬁrst 65 days
post-transplant) was associated with protection from CMV-related
complications. Inter- and intraassay variability of the assay was
8% and 8%, and results were available in 3 hours. Conclu-
sions: CMV tetramer-based immune monitoring, in conjunction
with virologic monitoring, can be an important new tool that
permits clinicians to assess the period of risk of CMV-related
complications and to make appropriate preemptive therapeutic
choices in managing allogeneic SCT patients. For high-risk pa-
tients with delayed immunologic recovery, virologic monitoring,
CMV tetramer monitoring, and other preemptive strategies should
be continued beyond 100 days post-transplant. For low-risk pa-
tients (7 tetramer-positive cells/mL), studies are needed to de-
termine how long virologic monitoring should be continued or if
preemptive therapy may be modiﬁed or instituted at higher viral
load levels (Table 1).
Table 1. Relative Risk
Recurrent or
Persistent
CMV Infection
CMV
Disease
Transplant-
Related
Mortality
Composite
(one or More
of These
Outcomes)
Delayed recovery
of CMV-specific
CD8 cells
(< 7 cells/uL)
2.6 4.8 2.4 2.2
P  .02 P  .09 P  .12 P  .01
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EFFECTS OF THYMOGLOBULIN ON LYMPHOCYTE L-SELECTIN-MEDI-
ATED ADHESIVE INTERACTIONS
Buzney, C.1, Lee, J.1, Sackstein, R.1,2 1. Brigham and Women’s Hos-
pital/Harvard Medical School, Boston, MA; 2. Dana-Farber Cancer
Institute, Boston, MA.
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